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Background: Acute ischemic stroke (AIS) is one of the leading causes of death and adult disability worldwide.
In the present study, we aimed to develop a web-based risk model for predicting dynamic functional status at
discharge, 3-month, 6-month, and 1-year after acute ischemic stroke (Dynamic Functional Status after Acute Ischemic
Stroke, DFS-AIS).
Methods: The DFS-AIS was developed based on the China National Stroke Registry (CNSR), in which eligible patients
were randomly divided into derivation (60%) and validation (40%) cohorts. Good functional outcome was defined as
modified Rankin Scale (mRS) score≤ 2 at discharge, 3-month, 6-month, and 1-year after AIS, respectively. Independent
predictors of each outcome measure were obtained using multivariable logistic regression. The area under the
receiver operating characteristic curve (AUROC) and plot of observed and predicted risk were used to assess model
discrimination and calibration.
Results: A total of 12,026 patients were included and the median age was 67 (interquartile range: 57–75). The
proportion of patients with good functional outcome at discharge, 3-month, 6-month, and 1-year after AIS was
67.9%, 66.5%, 66.9% and 66.9%, respectively. Age, gender, medical history of diabetes mellitus, stroke or transient
ischemic attack, current smoking and atrial fibrillation, pre-stroke dependence, pre-stroke statins using, admission
National Institutes of Health Stroke Scale score, admission blood glucose were identified as independent predictors of
functional outcome at different time points after AIS. The DFS-AIS was developed from sets of predictors of mRS≤ 2 at
different time points following AIS. The DFS-AIS demonstrated good discrimination in the derivation and validation
cohorts (AUROC range: 0.837-0.845). Plots of observed versus predicted likelihood showed excellent calibration in
the derivation and validation cohorts (all r = 0.99, P < 0.001). When compared to 8 existing models, the DFS-AIS
showed significantly better discrimination for good functional outcome and mortality at discharge, 3-month, 6-month,
and 1-year after AIS (all P < 0.0001).
Conclusion: The DFS-AIS is a valid risk model to predict functional outcome at discharge, 3-month, 6-month,
and 1-year after AIS.
Keywords: Acute ischemic stroke, Prognosis, Risk model* Correspondence: yongjunwang1962@gmail.com
1Tiantan Comprehensive Stroke Center, Beijing Tiantan Hospital, Capital
Medical University, No. 6 Tiantanxili, Beijing 100050, Dongcheng District,
China
2China National Clinical Research Center for Neurological Diseases
(NCRC-ND), Beijing, China
Full list of author information is available at the end of the article
© 2014 Ji et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Ji et al. BMC Neurology 2014, 14:214 Page 2 of 11
http://www.biomedcentral.com/1471-2377/14/214Background
Stroke is one of the leading causes of death and adult
disability worldwide and acute ischemic stroke (AIS)
accounts for about 85% of all stroke cases [1,2]. At time
of admission, clinicians are frequently requested to estimate
the likelihood of good functional outcome in post-stroke
period. During the past decades, a number of prognostic
models for AIS have been developed [3-18]. Except the
IScore and ASTRAL score [15,17], majority of them have
not been externally validated. Meanwhile, none of them is
recommended by international stroke guidelines and widely
used in routine clinical practice or clinical trials [3,19].
In addition, the majority of existing models are designed
to provide prognostic information for a single time
point after AIS, such as at discharge [13], 30-day [10],
3-month [4-7,9,17], 6-month [14], 9-month [16] or 1-year
[8,11] after onset. Although few recently proposed risk
models could provide dynamic prognostic information at
multiple time points after AIS [15,18], they mainly focused
on mortality instead of functional status. In real-world
practice, patients, family members, clinicians and re-
searchers usually concern about not only the likelihood
of survival, but also the likelihood of survival with
function recovery after AIS.
In the study, we aimed to develop and validate a risk
model to provide dynamic prognostic information on func-
tional status at multiple time points (discharge, 3-month,
6-month, and 1-year) after AIS (Dynamic Functional Status
after Acute Ischemic Stroke, DFS-AIS). Furthermore,
we compared discrimination of the DFS-AIS and exist-
ing AIS models with regard to both functional outcome




The derivation and validation cohort originated from the
largest stroke registry in China, the China National Stroke
Registry (CNSR) [20], which was a nationwide, multicenter,
and prospective registry of consecutive patients with acute
cerebrovascular events from September 2007 to August
2008. Briefly, hospitals in China are classified into 3 Levels:
I (community hospitals); II (hospitals that serve several
communities); and III (central hospitals for a certain
district or city). Level III hospital is usually an academic
center and more medically advanced than level I and II
hospitals. Totally, 242 potential sites including 114
Level III, 71 Level II, and 57 Level I hospitals, from both
urban and rural area, were initially identified by soliciting
application. The CNSR steering committee evaluated
research capability and commitment to the registry of
each hospital with preliminary survey. Finally, a total of
132 hospitals including 100 Level III and 32 Level II were
selected, which cover 27 provinces and 4 municipalitiesacross China. Trained research coordinators at each
institute reviewed medical records daily to identify,
consent and enroll consecutively eligible patients. To
be eligible for this study, subjects had to meet the
following criteria: (1) age 18 years or older; (2) hospital-
ized with a primary diagnosis of AIS according to the
World Health Organization criteria [21]; (3) stroke
confirmed by head computerized tomography (CT) or
brain magnetic resonance imaging (MRI); (4) direct
admission to hospital from a physician’s clinic or emer-
gency department; (5) written informed consent from
patients or their legal representatives. For the present
study, patients who received thrombolysis (n = 389,
3.1%) (Additional file 1: Table S1) were excluded since
thrombolysis alters the natural history of disability after
stroke [22]. However, they were included in sensitivity
analysis. The scientific use of data registered in the
CNSR was approved by the central institutional review
board at Beijing Tiantan hospital and local ethical com-
mittees at each participating hospital (Additional file 1).
Data collection and variables definition
Standardized case report form (CRF) was used for data
collection in the CNSR network. The relevant data was
extracted from the medical records by trained research
coordinators. Data from each CRF were manually checked
for completeness, correct coding, and proper application
of diagnostic algorithm by a research specialist from an
independent contract research organization. In the study,
the following candidate variables were analyzed: (1) demo-
graphics (age and gender); (2) stroke risk factors: hyper-
tension (history of hypertension or anti-hypertensive
medication use), diabetes mellitus (history of diabetes
mellitus or anti-diabetic medication use), dyslipidemia
(history of dyslipidemia or lipid-lowering medication use),
atrial fibrillation (history of atrial fibrillation or documen-
tation of atrial fibrillation on admission), coronary heart
disease, history of stroke/TIA, current smoking, and
excess alcohol consumption (≥2 standard alcohol bever-
ages per day); (3) pre-existing comorbidities: congestive
heart failure, valvular heart disease, peripheral artery
disease, chronic obstructive pulmonary disease (COPD),
hepatic cirrhosis, peptic ulcer or previous gastrointes-
tinal bleeding (GIB), renal failure, Alzheimer’s disease/
dementia, and cancer; (4) pre-stroke dependence (modi-
fied Rankin Scale score ≥ 3); (5) pre-admission antithrom-
botic medications: anticoagulant with warfarin (for atrial
fibrillation) or anti-platelet medication (aspirin, clopi-
dogrel, or extended release dipyridamole combined with
aspirin); (6) pre-admission statins using; (7) transporta-
tion mode to hospital (dichotomized as by emergency
medical system [EMS] or private transportation [such
as by taxi or private car]); (8) Time from onset to hos-
pital arrival (hours); (9) admission systolic and diastolic
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based on National Institutes of Health Stroke Scale
(NIHSS) score; (11) stroke subtypes according to the
Oxfordshire Community Stroke Project (OCSP) criteria
[23], where AIS was classified into partial anterior
circulation infarct (PACI), total anterior circulation
infarct (TACI), lacunar infarction (LACI), and posterior
circulation infarct (POCI). We did not use TOAST
subtype because it requires the results of investigations
that usually are not available at the time of admission
for many patients; (12) admission blood glucose (mmol/L).
Functional outcome assessment
The modified Rankin Scale (mRS) was used to assess
functional outcome at different time points (discharge,
3-month, 6-month and 1-year) after AIS. Treating phys-
ician evaluated patients’ functional status at discharge.
A central follow-up for functional status at 3-month,
6-month and 1-year after onset was made by telephone
interview by trained interviewers based on a standard-
ized interview protocol. Good functional outcome was
defined as mRS ≤ 2 at discharge, 3-month, 6-month, and
1-year after AIS, respectively.
Statistical analysis
We aimed to derivate and validate a risk model to predict
functional outcome at multiple time points (discharge,
3-month, 6-month, and 1-year) after AIS by using patient
characteristics commonly available at presentation. In
order to guarantee the accuracy of prediction, we separ-
ately developed 4 prognostic rules for each outcome
measures. For the practicability of the model, we devel-
oped a web-based and user-friendly calculator, which can
automatically provide prognostic information at differ-
ent time points after AIS.
The eligible patients (an additional figure shows this in
more detail [see Additional file 1: Figure S1]) in the
CNSR were randomly divided into derivation (60%) and
validation (40%) cohorts. Model building was performed
exclusively in the derivation cohort (n = 7,215). In univari-
ate analysis, Chi-square or Mann–Whitney test was used
as appropriate. Multivariate logistic regression was used to
determine independent predictors of good functional
outcome (mRS ≤ 2) at discharge, 3-month, 6-month and
1-year after AIS, respectively. Candidate variables were
those with biologically plausible link to good functional
outcome after AIS on the basis of prior publication and
those associated with good functional outcome after
AIS on univariate analysis (P ≤ 0.1). On multivariate
analysis, backward stepwise method was used. To test
for collinearity between covariates of the final multivariable
model, the tolerance and variance inflation factor (VIF) of
each covariate were calculated. The resulting DFS-AIS was
then validated by assessing model discrimination andcalibration in the validation cohort (n = 4,811) [24].
Discrimination was assessed by calculating the area under
the receiver operating characteristic curve (AUROC).
Calibration was assessed by performing the Hosmer-
Lemeshow goodness-of-fit test. Due to that the Hosmer-
Lemeshow test has been shown to be overly sensitive to
trivial deviations from the ideal fit when the sample size is
large [25], model calibration was also graphically depicted
in the plot of observed versus predicted risk according to
10 deciles of predicted risk.
Furthermore, we compared discrimination of the DFS-
AIS and existing AIS models with regard to both func-
tional outcome (mRS ≤ 2) and mortality at discharge,
3-month, 6-month and 1-year after AIS in the overall
cohort (n = 12,026). The primary criterion for selection
of compared model was whether all elements required
for the model were available in our dataset. Meanwhile,
due to that a systematical review on prognostic models
of acute stroke published in 2001 indicated that none
of the existing prognostic models have been suffi-
ciently well developed and validated to be useful in
either clinical practice or research, we included only
AIS risk models developed after 2001. Finally, 8 risk
models (the Weimar’s survival and functional model
[9], König’s survival and functional model [12], GWTG
score [13], IScore [15], ASTRAL score [17], and PLAN
score [18]) were selected. Discrimination of these models
(AUROC) was compared using the test proposed by
Delong et al. [26]. Sensitivity, specificity, positive predict
value (PPV), and negative predictive value (NPV) was
calculated at each model’s maximum Youden Index.
Missing data were coded as following: 25 patients (0.2%)
with missing data on medical history of current smoking,
110 (0.9%) of excess alcohol consumption, 30 (0.2%) of
Alzheimer disease/dementia, 50 (0.4%) of hepatic cirrhosis
were coded as absence. Sixty-sever patients (0.6%) with
missing or unknown time from stroke onset to hospital
arrival were coded as median.
All tests were 2-tailed and statistical significance was
determined at α level of 0.05. Regarding the number of
comparisons done in comparing discrimination of prog-
nostic models, we use more restricted criterion (0.001)
to declare significant difference. Statistical analysis was
performed using SAS 9.3 (SAS Institute, Cary, NC), SPSS




Patient characteristics of the derivation and validation
cohorts are shown in Table 1. From September 2007 to
August 2008, a total of 12,026 patients in the CNSR
were eligible for the study and included in final analysis
(an additional figure shows this in more detail [see









Age, y, median (IQR) 67 (57–75) 67 (57–75) 67 (57–75) 0.35
Gender (male), n (%) 7411 (61.6) 4461 (61.8) 2950 (61.3) 0.58
Stroke risk factors, n (%)
Hypertension 7703 (64.1) 4602 (63.8) 3101 (64.5) 0.46
Diabetes mellitus 2615 (21.7) 1580 (21.9) 1035 (21.9) 0.62
Dyslipidemia 1349 (11.2) 797 (11.0) 552 (11.5) 0.47
Atrial fibrillation 870 (7.2) 543 (7.5) 327 (6.8) 0.13
Coronary artery disease 1714 (14.3) 1063 (14.7) 651 (13.5) 0.07
History of stroke/TIA 4113 (33.6) 2403 (33.3) 1635 (34.0) 0.44
Current Smoking 4750 (39.5) 2846 (39.4) 1904 (39.6) 0.89
Excess alcohol consumption 1844 (15.3) 1124 (15.6) 720 (15.0) 0.37
Pre-existing comorbidities, n (%)
Congestive heart failure 239 (2.0) 151 (2.1) 88 (1.8) 0.32
Valvular heart disease 284 (2.4) 171 (2.4) 113 (2.3) 0.95
COPD 138 (1.1) 80 (1.1) 58 (1.2) 0.66
Hepatic cirrhosis 42 (0.4) 24 (0.3) 18 (0.4) 0.76
Peptic ulcer or previous GIB 411 (3.4) 235 (3.3) 178 (3.7) 0.24
Alzheimer’s disease/Dementia 166 (1.4) 95 (1.3) 71 (1.5) 0.47
Cancer 222 (1.8) 140 (1.9) 82 (1.7) 0.36
Pre-stroke dependence (mRS ≥ 3), n (%) 1140 (9.5) 684 (9.5) 456 (9.5) 0.99
Pre-admission antithrombotic therapy, n (%) 2246 (18.7) 1345 (18.6) 901 (18.7) 0.91
Warfarin (for atrial fibrillation) 272 (2.3) 170 (2.4) 102 (2.1)
Antiplatelet using 2208 (16.7) 1201 (16.6) 807 (16.8)
Pre-admission statins using, n (%) 5175 (43.0) 3066 (42.5) 2109 (43.8) 0.15
Transport to hospital by EMS, n (%) 1826 (15.2) 1075 (14.9) 751 (15.6) 0.29
Time from onset to arrival (hours), median (IQR) 24 (7–64) 24 (7–64) 24 (7–65) 0.83
Admission SBP (mm Hg), median (IQR) 150 (136–164) 150 (135–163) 150 (136–164) 0.76
Admission DBP (mm Hg), median (IQR) 89 (80–96) 89 (80–96) 89 (80–96) 0.67
Admission NIHSS score, median (IQR) 5 (2–9) 5 (2–10) 5 (2–9) 0.33
NIHSS = 0-4 6152 (51.2) 3686 (51.1) 2466 (51.3) 0.31
NIHSS = 5-9 3159 (26.3) 1873 (26.0) 1286 (26.7)
NIHSS = 10-14 1312 (10.9) 783 (10.9) 529 (11.0)
NIHSS ≥ 15 1403 (11.7) 873 (12.1) 530 (11.0)
OCSP subtypes, n (%) 0.69
Partial anterior circulation infarct (PACI) 6698 (55.7) 4025 (55.8) 2673 (55.6)
Total anterior circulation infarct (TACI) 1035 (8.6) 623 (8.6) 412 (8.6)
Lacunar infarction (LACI) 2252 (18.7) 1365 (18.9) 887 (18.4)
Posterior circulation infarct (POCI) 2009 (17.1) 1180 (16.8) 829 (17.6)
Admission blood glucose (mmol/L), median (IQR) 6.2 (5.5-7.0) 6.2 (5.5-7.0) 6.2 (5.5-7.1) 0.30
Length of hospital stay, median (IQR) 14 (10–20) 14 (10–20) 14 (11–20) 0.55
mRS≤ 2 within 1 year after onset, n (%)
At discharge 8160 (67.9) 4885 (67.7) 3275 (68.1) 0.68
At 3-month 7994 (66.5) 4771 (66.1) 3223 (67.0) 0.33
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Table 1 Patient characteristics (Continued)
At 6-month 8050 (66.9) 4806 (66.6) 3244 (67.4) 0.35
At 12-mont 8047 (66.9) 4817 (66.8) 3230 (67.1) 0.68
Mortality within 1 year after onset, n (%)
At discharge 468 (3.9) 276 (3.8) 192 (4.0) 0.67
At 3-month 990 (8.2) 606 (8.4) 384 (8.0) 0.44
At 6-month 1270 (10.6) 774 (10.7) 496 (10.3) 0.49
At 12-mont 1602 (13.2) 995 (13.8) 607 (12.6) 0.07
Abbreviation: IQR Interquartile Range, TIA Transient Ischemic Attack, COPD Chronic obstructive pulmonary disease, mRS Modified Rankin Scale, EMS Emergency
Medical System, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure, NIHSS National Institutes of Health Stroke Scale score, OCSP Oxfordshire Community
Stroke Project.
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(IQR 57–75) and 61.6% were male. The median length
of hospital stay was 14 days (IQR: 10–20). The median
admission NIHSS score was 5 (IQR: 2–9). The proportion
of good functional outcome (mRS ≤ 2) at discharge,
3-month, 6-month, and 1-year after AIS was 67.9%,
66.5%, 66.9% and 66.9%, respectively. The eligible
patients were randomly divided into derivation (60%,
n = 7,215) and validation cohort (40%, n = 4,811), which
were matched with respect to baseline characteristics and
overall rate of good functional outcome (mRS ≤ 2) at
different time points following AIS (Table 1).
Derivation of the DFS-AIS
The multivariate analysis for predictors of good functional
outcome (mRS ≤ 2) at discharge, 3-month, 6-month, and
1-year after AIS is shown in Table 2. Age, gender, medical
history of diabetes mellitus, stroke/TIA (for mRS ≤ 2 at
3-month, 6-month and 1-year after onset), current smoking
(for mRS ≤ 2 at discharge) and atrial fibrillation (for
mRS ≤ 2 at 3-month, 6-month and 1-year after onset),
pre-stroke dependence, pre-stroke statins using (for
mRS ≤ 2 at 3-month, 6-month and 1-year after onset),
admission NIHSS score, admission blood glucose were
identified as independent predictors of functional out-
come at different time points after AIS. The tolerance
of covariates in the final multivariable model ranged
0.80-0.99 and the VIF 1.01-1.21 (Table 2). The probability
of good functional outcome (mRS ≤ 2) at discharge,
3-month, 6-month, and 1-year after AIS can be estimated
for an individual patient by a web-based calculator
(Figure 1) (www.dfs-ais.com).
Validation of the DFS-AIS
Discrimination of the DFS-AIS with regard to good
functional outcome (mRS ≤ 2) at discharge, 3-month,
6-month, and 1-year after AIS is shown in Additional
file 1: Figure S2 (an additional figure shows this in more
detail [see Additional file 1: Figure S2]). Similar good
discrimination was found in both the derivation (AUROCrange: 0.842-0.845) and validation cohort (AUROC range:
0.837-0.841). The Hosmer-Lemeshow tests of the DFS-
AIS for good functional outcome at discharge, 3-month,
6-month, and 1-year after AIS were significant in the
validation cohort (all P < 0.001). However, a graph of
observed versus predicted likelihood of good functional
outcome at discharge, 3-month, 6-month, and 1-year
after AIS showed a close correlation between observed
and predicted risk in both the derivation and validation
cohorts (all r = 0.99, P < 0.001) (an additional figure shows
this in more detail [see Additional file 1: Figure S3]), which
indicated excellent calibration.
Sensitivity analysis
We completed pre-specified subgroup analyses by age,
gender, time intervals from stroke onset to arrival, OCSP
subtype and thrombolysis. Similar good discrimination
was seen in these subgroups (AUROC range: 0.773-0.917),
especially for those patients with TACI subtype (AUROC
range: 0.855-0.917) (Table 3).
Comparison of AIS risk models
Discrimination of the DFS-AIS and 8 existing AIS models
for good functional outcome (mRS ≤ 2) and mortality at
discharge, 3-month, 6-month and 1-year after AIS in
the validation cohort (n = 4,811) is shown in Figure 2
(additional tables show this in more detail [see Additional
file 1: Table S2 and S3]). For good functional outcome
prediction, although all tested models showed accept-
able discrimination (AUROC ≥ 0.70), the DFS-AIS dem-
onstrated significantly higher AUROC than other models
(all P < 0.0001). Meanwhile, the DFS-AIS had the highest
maximum Youden Index and associated sensitivity, speci-
ficity, PPV and NPV (an additional table shows this in
more detail [see Additional file 1: Table S2]). Similar
results were found for predicting mortality at discharge,
3-month, 6-month, and 1-year after AIS (Figure 2 and
Additional file 1: Table S3). When the comparison was
performed in the overall cohort (n = 12,026), similar results
was found (see Additional file 1: Table S4 and S5).
Table 2 Multivariable analysis
Predictors Discharge mRS≤ 2* 3-month mRS≤ 2* 6-month mRS≤ 2* 1-year mRS≤ 2*
ß-coefficient OR (95% C.I.) P ß-coefficient OR (95% C.I.) P ß-coefficient OR (95% C.I.) P ß-coefficient OR (95% C.I.) P
Intercept 2.855 4.010 4.355 3.892
Age (per 1 year increase) −0.02 0.98 (0.97-0.98) <0.0001 −0.043 0.96 (0.95-0.96) <0.0001 −0.050 0.95 (0.95-0.96) <0.0001 −0.058 0.94 (0.94-0.95) <0.0001
Gender (male) 0.295 1.34 (1.19-1.52) <0.0001 0.234 1.26 (1.14-1.40) <0.0001 0.189 1.21 (1.09-1.34) <0.0001 0.274 1.32 (1.18-1.47) <0.0001
Risk factors
Diabetes mellitus (No) 0.204 1.23 (1.08-1.39) 0.001 0.289 1.34 (1.17-1.52) <0.0001 0.296 1.34 (1.18-1.53) <0.0001 0.239 1.27 (1.11-1.45) <0.0001
Stroke/TIA (No) … … … 0.278 1.32 (1.18-1.49) <0.0001 0.316 1.37 (1.22-1.55) <0.0001 0.371 1.45 (1.30-1.62) <0.0001
Current smoking (No) 0.157 1.17 (1.03-1.33) 0.01 … … … … … … … … …
Atrial fibrillation (No) … … … 0.218 1.24 (1.02-1.52) 0.03 0.230 1.26 (1.03-1.53) 0.03 0.303 1.35 (1.11-1.65) 0.003
Pre-stroke independence
(mRS≤ 2)
0.549 1.73 (1.47-2.04) <0.0001 0.588 1.80 (1.51-2.15) <0.0001 0.672 1.96 (1.65-2.33) <0.0001 0.634 1.89 (1.58-2.22) <0.0001
pre-stroke statins using (Yes) … … … 0.198 1.22 (1.10-1.35) <0.0001 0.213 1.24 (1.12-1.37) <0.0001 0.263 1.30 (1.17-1.44) <0.0001
Admission NIHSS score
(per 1 increase)
−0.197 0.82 (0.81-0.83) <0.0001 −0.211 0.81(0.80-0.82) <0.0001 −0.196 0.82 (0.81-0.83) <0.0001 −0.185 0.83 (0.82-0.84) <0.0001
Admission BG (per 1 mmol/L
increase)
−0.044 0.96 (0.94-0.98) <0.0001 −0.043 0.95 (0.93-0.97) <0.0001 −0.054 0.95 (0.93-0.97) <0.0001 −0.061 0.94 (0.92-0.96) <0.0001
Multivariable logistic regression adjusted for age, gender, stroke risk factors, pre-existing comorbidities, pre-stroke dependence, pre-admission medications (anticoagulant with warfarin, anti-platelet medication, and
statins), transport model to hospital, time from onset to hospital arrival, admission systolic and diastolic blood pressure, NIHSS score, OCSP subtypes, and admission blood glucose.
*Probability of good functional outcome (mRS ≤ 2) is calculated by P = eY/(1 + eY), where Y = a + b1X1 + b2X2 +∴.. + biXi;

















Figure 1 The web-based calculator for the DFS-AIS.
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In the study, we developed and validated a risk model
to predict functional outcome at multiple time points
(discharge, 3-month, 6-month, and 1-year) after AIS by
using information routinely available at presentation.Table 3 Sensitivity analysis of the DFS-AIS in the overall coho
Discharge mRS≤ 2 3-mo
AUROC 95% C.I. AUR
Age
≤59 0.845 0.829-0.861 0.82
≥60 0.830 0.820-0.839 0.83
Gender
Male 0.834 0.823-0.845 0.83
Female 0.843 0.830-0.856 0.84
Time from onset to arrival (hours)
≤3 0.829 0.808-0.850 0.84
3-6 0.838 0.808-0.868 0.82
6-24 0.834 0.818-0.850 0.84
≥24 0.845 0.833-0.856 0.84
OCSP subtype
Lacunar infarction (LACI) 0.809 0.785-0.833 0.81
Partial anterior circulation infarct (PACI) 0.827 0.816-0.838 0.82
Total anterior circulation infarct (TACI) 0.855 0.830-0.880 0.91
Posterior circulation infarct (POCI) 0.853 0.833-0.873 0.84
Intravenous or intra-arterial thrombolysis 0.773 0.724-0.822 0.78
Abbreviation: mRS Modified Rankin Scale, AUROC Area Under the Receiver Operating
Stroke Project.A web-based risk model (the DFS-AIS) was developed
based on the set of independent predictors of each out-
come measures and showed good discrimination and
calibration in large derivation and validation cohorts.
When compared to 8 existing models, the DFS-AISrt (n = 12,026)
nth mRS≤ 2 6-month mRS≤ 2 1-year mRS≤ 2
OC 95% C.I. AUROC 95% C.I. AUROC 95% C.I.
6 0.808-0.844 0.820 0.801-0.839 0.813 0.793-0.833
6 0.826-0.846 0.830 0.820-0.840 0.827 0.817-0.837
2 0.821-0.843 0.834 0.823-0.845 0.834 0.823-0.845
9 0.837-0.861 0.846 0.834-0.858 0.845 0.833-0.857
6 0.825-0.867 0.847 0.826-0.868 0.857 0.837-0.877
6 0.796-0.856 0.836 0.807-0.865 0.834 0.805-0.863
5 0.830-0.860 0.842 0.827-0.857 0.848 0.833-0.862
1 0.829-0.853 0.839 0.828-0.850 0.831 0.819-0.842
9 0.796-0.842 0.829 0.807-0.851 0.816 0.794-0.838
1 0.810-0.832 0.822 0.811-0.833 0.826 0.815-0.837
7 0.900-0.936 0.912 0.892-0.932 0.905 0.885-0.925
6 0.826-0.866 0.840 0.820-0.860 0.845 0.826-0.846
5 0.735-0.833 0.779 0.733-0.825 0.781 0.730-0.832
Characteristic Curve, C.I. Confidence Interval, OCSP Oxfordshire Community
Figure 2 Comparative evaluation of the DFS-AIS and 8 existing AIS models. Figure 2 showed discrimination of the DFS-AIS and 8 existing
AIS models with regard to good functional outcome (mRS≤ 2) and mortality at discharge, 3-month, 6-month, and 1-year after AIS in the validation
cohort (n = 4,811). The DFS-AIS consistently showed significant better discrimination than compared models with regard to both good functional
outcome (mRS ≤ 2) and mortality at discharge, 3-month, 6-month, and 1-year after AIS (all P < 0.0001).
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to both functional outcome and mortality at discharge,
3-month, 6-month, and 1-year after AIS.
In order to preserve clinical utility of the model for
decision-making during acute hospitalization and post-
discharge, we used only patient characteristics available at
presentation. We chose not to include variables related to
in-hospital and postdischarge management, such as intra-
venous recombinant tissue plasminogen activator (rt-PA)
[22], rehabilitation, and persistence of evidence-based
secondary prevention medications [27-29], despite the
fact that these therapies could influence functional
status following AIS. This model therefor predicts the
expected functional status following AIS at presentation.
For a clinical prognostic rule to become effective and
widely used, it must be reliable, accurate and practicable
[3]. For reliability, the DFS-AIS was developed based on
large derivation and validation cohorts, which included
consecutive patients of AIS from a nationwide stroke
registry, was outside of clinical trials, and was more
reflective of real-world clinical practice; In addition, by
sensitivity analysis, the DFS-AIS demonstrated to be
effective for patients with various clinical characteristics,
such as different age, gender, time intervals from stroke
onset to hospital arrival, and OCSP subtype. For accuracy,
the DFS-AIS was proven to be accurate in risk-stratification
and outcome prediction for both functional outcome
and mortality at multiple time points after AIS. For
practicability, the DFS-AIS consists of factors that are
readily available at hospital presentation. In addition, bya web-based and user-friendly calculator, users could
obtain prognostic information at multiple time points
following AIS without doing complex calculation.
To the best of our knowledge, we are the first to sys-
tematically compare AIS risk models in a single popula-
tion. During the past decades, a multitude of AIS predictive
models have been developed. Although each of these
prognostic rules has inherent strengths and limitations,
none of them is widely accepted and used in routine
clinical practice or clinical trials [3,19]. With many AIS
prognostic rules available, identification of the most
accurate and reliable model(s) would be of great value
to patients, family members, clinicians, and researchers.
In this study, we found that the DFS-AIS consistently
demonstrated significant better discrimination than 8
compared models for both functional outcome and
mortality at discharge, 3-month, 6-month, and 1-year
after AIS (Figure 2, Table S1, and S2). Though promising,
one should exercise caution when interpreting the results:
first, the study populations for derivation and validation
of these AIS risk models are different. The clinical char-
acteristics of our study population were different from
those of western cohorts used to develop compared
models [13,15,17,18], such as with younger age of AIS
onset, higher proportion of male gender, less severity of
neurological deficit on admission, and lower rate of
mortality at different time points following AIS. It is not
our primary aim to compare difference of these cohorts
and it is hard to explain the potential reasons due
to sorts of difference in study design and population.
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economic factors as well as regional management phil-
osophies and preferences that are difficult to account
for when prognostic models are developed or applied to
a distinct population. Finally, the intended outcome
(functional outcome vs. mortality), outcome assessment
methods (Barthel Index vs. mRS), and timing of follow-
up (in-hospital vs. 30-day vs. 3-month vs. 6-month vs.
1-year after AIS) are different for these AIS models.
One might argue it is not fair to directly compare these
models for functional outcome and mortality at various
time points after AIS as that they were not designed in
that way. However, our intention was not to show limi-
tation of these models beyond the context under which
they are developed, but to provide evidence on which
model is more appropriate for what kind of outcome
(functional outcome vs. mortality) and at what specific
time points (discharge, 3-month, 6-month, and 1-year)
after AIS.
By offering prediction of functional outcome at multiple
time points following AIS, rather than only mortality, the
DFS-AIS can be useful for patients, family members,
clinicians and researchers, whose primary concern is
not the likelihood of survival, but rather the likelihood of
survival with recovery of function. This is also important
since different clinical care contexts or clinical research
may focus on short-term or long-term functional outcome
after AIS differently. Meanwhile, the DFS-AIS could be
used to monitor the performance of hospitals or stroke
units in stroke care. Those hospitals or stroke units which
deviate in outcome from the expected outcome (e.g. worse
outcome) need to be monitored in detail to identify the
potential targets for improvement. In addition, like other
prognostic tools, the DFS-AIS may help in randomized
clinical trials to stratify study population, in nonrando-
mized clinical trials to control for case-mix variation, and
in controlled clinical trials to select suitable patients and
to reduce required sample size [19,30,31].
Our study has limitations that deserve comment. First,
like all observational studies, we cannot rule out the possi-
bility that additional variable (unmeasured confounders)
might have some impact on functional status after stroke,
such as intravenous rt-PA, neuroimaging characteristics,
rehabilitation, and persistence of evidence-based second-
ary prevention medications. However, given our emphasis
on early prediction using information at presentation
to predict dynamic functional outcome after AIS, the
DFS-AIS might be helpful to guide subsequent in-hospital
and post-discharge management. Second, our study
included only hospitalized stroke patients and those
patients died in emergency department or treated in
outpatient clinics were not included. Meanwhile, like
most registries, our registry required informed consent
and selection bias was inevitable [32]. Third, due to thatthe Medical Research Council score, volume of ischemia
on diffusion-weighted imaging, Charlson comorbidity
index, Consortium for the Investigation of Vascular
Impairment of Cognition scale score, body temperature,
and oxygen administration were not routinely collected
in the CNSR, several other AIS models cannot be exter-
nally validated in the study [4-6,8,11,14,16]. Finally, the
DFS-AIS is not externally validated in the study. Mean-
while, both the derivation and validation cohorts origi-
nated from Asian population, and therefore, the score
needed to be further validated in non-Asian populations.Conclusion
The DFS-AIS is a valid clinical model for predicting
functional outcome at discharge, 3-month, 6-month, and
1-year after AIS. For clinical practice, the DFS-AIS can
be useful for patients, family members, and clinicians by
offering prediction of functional outcome at multiple
time points following AIS. For clinical research, the
DFS-AIS may help in randomized clinical trials to strat-
ify study population, in nonrandomized clinical trials to
control for case-mix variation, and in controlled clinical
trials to select suitable patients and to reduce required
sample size. Further validation of the DFS-AIS in differ-
ent populations is required.Additional file
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